Preferential Loss of Contrast Decrement Responses in Human Glaucoma.


Journal

Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701

Informations de publication

Date de publication:
03 10 2022
Historique:
entrez: 20 10 2022
pubmed: 21 10 2022
medline: 25 10 2022
Statut: ppublish

Résumé

The purpose of this study was to determine whether glaucoma in human patients produces preferential damage to OFF visual pathways, as suggested by animal experimental models, patient electroretinogram (ERG), and retinal imaging data. Steady-state visual evoked potentials (SSVEPs) were recorded monocularly from 50 patients with glaucoma and 28 age-similar controls in response to equal Weber contrast increments and decrements presented using 2.73 hertz (Hz) sawtooth temporal waveforms. The eyes of patients with glaucoma were separated into mild (better than -6 decibel [dB] mean deviation; n = 28) and moderate to severe (worse than -6 dB mean deviation, n = 22) groups based on their Humphrey 24-2 visual field measurements. Response amplitudes and phases from the two glaucoma-severity groups were compared to controls at the group level. SSVEP amplitudes were depressed in both glaucoma groups, more so in the moderate to severe glaucoma group. The differences between controls and the moderate-severe glaucoma groups were more statistically reliable for decrements than for increments. Mean responses to decremental sawtooth stimuli were larger than those to increments in controls and in the mild glaucoma but not in the moderate to severe glaucoma group at the first harmonic. OFF/decrement responses at the first harmonic were faster in controls, but not in patients. The observed pattern of preferential loss of decremental responses in human glaucoma is consistent with prior reports of selective damage to OFF retinal ganglion cells in murine models and in data from human ERG and retinal imaging. These data motivate pursuit of SSVEP as a biomarker for glaucoma progression.

Identifiants

pubmed: 36264656
pii: 2783779
doi: 10.1167/iovs.63.11.16
pmc: PMC9587510
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

16

Subventions

Organisme : NEI NIH HHS
ID : P30 EY026877
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY030361
Pays : United States

Références

J Neurodegener Dis. 2017;2017:9540609
pubmed: 28808597
Invest Ophthalmol Vis Sci. 2022 Jan 3;63(1):18
pubmed: 35024761
Invest Ophthalmol Vis Sci. 1983 Feb;24(2):175-83
pubmed: 6826322
Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):E2393-E2402
pubmed: 29463759
Exp Eye Res. 2017 Sep;162:97-103
pubmed: 28629926
Doc Ophthalmol. 2011 Feb;122(1):53-62
pubmed: 21267627
J Neurosci. 2013 Oct 30;33(44):17444-57
pubmed: 24174678
Vision Res. 1984;24(5):395-401
pubmed: 6740960
Indian J Physiol Pharmacol. 2013 Apr-Jun;57(2):123-31
pubmed: 24617161
J Physiol. 1967 May;190(1):139-54
pubmed: 6038016
Electroencephalogr Clin Neurophysiol. 1995 May;96(3):268-77
pubmed: 7750452
Doc Ophthalmol. 1987 Nov;67(3):281-301
pubmed: 3447853
Electroencephalogr Clin Neurophysiol. 1991 May;78(5):378-88
pubmed: 1711456
Neuron. 2019 Dec 18;104(6):1039-1055.e12
pubmed: 31784286
Br J Ophthalmol. 2006 Sep;90(9):1132-6
pubmed: 16707520
Cell Death Discov. 2018 Jun 28;4:7
pubmed: 30062056
Ophthalmology. 2006 Feb;113(2):216-28
pubmed: 16406535
J Neurosci. 2013 Sep 11;33(37):14958-73
pubmed: 24027295
Cereb Cortex. 2019 Jan 1;29(1):336-355
pubmed: 30321290
Vision Res. 1993 Sep;33(14):1997-2011
pubmed: 8249315
Br J Ophthalmol. 1992 May;76(5):264-7
pubmed: 1390506
Doc Ophthalmol. 2017 Oct;135(2):107-119
pubmed: 28702796
Exp Eye Res. 2017 May;158:43-50
pubmed: 27319294
Neuroimage. 2015 Apr 1;109:63-72
pubmed: 25579449
Nat Neurosci. 2008 Jan;11(1):88-94
pubmed: 18084287
J Zhejiang Univ Sci B. 2020 Apr.;21(4):305-314
pubmed: 32253840
Psychophysiology. 1998 Jan;35(1):99-115
pubmed: 9499711
Invest Ophthalmol Vis Sci. 1983 Nov;24(11):1524-8
pubmed: 6642932
Transl Vis Sci Technol. 2017 Nov 08;6(6):6
pubmed: 29134137
Transl Vis Sci Technol. 2020 Sep 04;9(10):6
pubmed: 32953246
Can J Ophthalmol. 2017 Feb;52(1):114-124
pubmed: 28237137
Invest Ophthalmol Vis Sci. 2013 Apr 23;54(4):2847-52
pubmed: 23513061
BMC Ophthalmol. 2017 May 22;17(1):77
pubmed: 28532392
Clin Exp Optom. 2020 Sep;103(5):562-571
pubmed: 31838755
Doc Ophthalmol. 2012 Jun;124(3):237-48
pubmed: 22457046
Am J Ophthalmol. 1989 May 15;107(5):453-64
pubmed: 2712129
Invest Ophthalmol Vis Sci. 2015 Oct;56(11):7000-6
pubmed: 26513506
JAMA Ophthalmol. 2017 Jun 1;135(6):550-557
pubmed: 28448641
J Neurosci. 2019 Mar 6;39(10):1881-1891
pubmed: 30622167
Doc Ophthalmol. 2008 Nov;117(3):233-43
pubmed: 18483820
Invest Ophthalmol Vis Sci. 2019 Oct 1;60(13):4270-4276
pubmed: 31618763
Asia Pac J Ophthalmol (Phila). 2018 Sep-Oct;7(5):352-355
pubmed: 29638049
J Physiol. 1965 Dec;181(4):881-94
pubmed: 5881260
J Neurosci. 2009 Sep 23;29(38):11753-60
pubmed: 19776262
Prog Retin Eye Res. 2021 Jan;80:100875
pubmed: 32659431
Int J Ophthalmol. 2017 Apr 18;10(4):599-604
pubmed: 28503434
Vision Res. 1998 Jun;38(12):1901-11
pubmed: 9797966
Invest Ophthalmol Vis Sci. 1994 May;35(6):2758-64
pubmed: 8188469
J Neurosci. 2016 Aug 31;36(35):9240-52
pubmed: 27581463
Vision Res. 1997 Jul;37(14):1975-87
pubmed: 9274782
J Neurosci. 2011 Nov 30;31(48):17471-9
pubmed: 22131408
Invest Ophthalmol Vis Sci. 2015 Feb 26;56(3):1971-84
pubmed: 25722210
J Neurosci. 2015 Feb 11;35(6):2329-43
pubmed: 25673829
Neuroreport. 1993 Sep 3;4(10):1159-62
pubmed: 8219010
Br J Ophthalmol. 2008 Sep;92(9):1287-92
pubmed: 18614574
Br J Ophthalmol. 1993 Jun;77(6):332-8
pubmed: 8318478
Proc Natl Acad Sci U S A. 2017 Aug 15;114(33):8859-8864
pubmed: 28760976
Invest Ophthalmol Vis Sci. 2006 Dec;47(12):5331-6
pubmed: 17122121
Graefes Arch Clin Exp Ophthalmol. 1988;226(6):542-7
pubmed: 3209081
Neuron. 2014 Apr 2;82(1):224-34
pubmed: 24698277
Annu Rev Vis Sci. 2020 Sep 15;6:47-89
pubmed: 32936738

Auteurs

Anthony M Norcia (AM)

Department of Psychology, Wu Tsai Neurosciences Institute, Stanford University, Stanford, California, United States.

Alexandra Yakovleva (A)

Spencer Center for Vision Research, Byers Eye Institute, Department of Ophthalmology, Stanford University, Stanford, California, United States.

Naz Jehangir (N)

Spencer Center for Vision Research, Byers Eye Institute, Department of Ophthalmology, Stanford University, Stanford, California, United States.

Jeffrey L Goldberg (JL)

Spencer Center for Vision Research, Byers Eye Institute, Department of Ophthalmology, Stanford University, Stanford, California, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH